Merck's Keytruda (pembrolizumab) has hit the mark in the late-stage NRG-GY018 trial, with a combination of the drug plus chemotherapy improving progression-free survival (PFS) versus chemo alone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback